Mustang Bio Inc
MBIO1.260USD
-0.070-5.26%
Market hours （ET）Quotes delayed by 15 min
21.30KMarket Cap
LossP/E TTM
More Details of Mustang Bio Inc Company
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Company Info
Company codeMBIO
Company nameMustang Bio Inc
IPO dateAug 22, 2017
Founded at2015
CEODr. Manuel Litchman, M.D.
Number of employees6
Security typeOrdinary Share
Fiscal year-endAug 22
Address377 Plantation Street
CityWORCESTER
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01605
Phone17816524500
Websitehttps://www.mustangbio.com/
Company codeMBIO
IPO dateAug 22, 2017
Founded at2015
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Manuel Litchman, M.D.
Dr. Manuel Litchman, M.D.
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
1.52K
--
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
392.00
--
Mr. Adam J. Chill
Mr. Adam J. Chill
Independent Director
Independent Director
379.00
--
Dr. Michael J. Zelefsky, M.D.
Dr. Michael J. Zelefsky, M.D.
Independent Director
Independent Director
379.00
--
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Director
Director
342.00
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Chairman of the Board
Executive Chairman of the Board
325.00
--
Mr. David Jin
Mr. David Jin
Director
Director
39.00
--
Name
Name/Position
Position
Shareholding
Change
Dr. Manuel Litchman, M.D.
Dr. Manuel Litchman, M.D.
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
1.52K
--
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
392.00
--
Mr. Adam J. Chill
Mr. Adam J. Chill
Independent Director
Independent Director
379.00
--
Dr. Michael J. Zelefsky, M.D.
Dr. Michael J. Zelefsky, M.D.
Independent Director
Independent Director
379.00
--
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Director
Director
342.00
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Chairman of the Board
Executive Chairman of the Board
325.00
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Wed, Apr 23
Update time: Wed, Apr 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Fortress Biotech Inc
8.08%
Intracoastal Capital, L.L.C.
4.45%
Armistice Capital LLC
2.93%
Geode Capital Management, L.L.C.
0.23%
Homrich Berg
0.09%
Other
84.22%
Shareholder Statistics
Shareholder
Proportion
Fortress Biotech Inc
8.08%
Intracoastal Capital, L.L.C.
4.45%
Armistice Capital LLC
2.93%
Geode Capital Management, L.L.C.
0.23%
Homrich Berg
0.09%
Other
84.22%
Type
Shareholder
Proportion
Corporation
12.53%
Hedge Fund
3.07%
Investment Advisor/Hedge Fund
0.41%
Investment Advisor
0.21%
Individual Investor
0.14%
Research Firm
0.05%
Venture Capital
0.02%
Other
83.56%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
97
1.25M
63.69%
+1.04M
2024Q4
107
246.39K
20.57%
+127.81K
2024Q3
122
111.37K
16.10%
+44.38K
2024Q2
137
71.29K
10.74%
+5.47K
2024Q1
164
58.94K
30.95%
-18.94K
2023Q4
172
59.40K
38.79%
+2.99K
2023Q3
181
115.34K
86.47%
+11.94K
2023Q2
197
115.47K
86.60%
+14.23K
2023Q1
214
111.30K
83.83%
+7.44K
2022Q4
221
110.31K
84.99%
+11.20K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fortress Biotech Inc
198.86K
8.08%
+67.81K
+51.74%
Mar 31, 2025
Intracoastal Capital, L.L.C.
109.50K
4.45%
+109.50K
--
Feb 05, 2025
Armistice Capital LLC
72.13K
2.93%
+33.91K
+88.72%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.69K
0.23%
+779.00
+15.87%
Dec 31, 2024
Homrich Berg
2.14K
0.09%
+1.34K
+167.50%
Dec 31, 2024
UBS Financial Services, Inc.
2.01K
0.08%
+1.90K
+1.70K%
Dec 31, 2024
Renaissance Technologies LLC
1.75K
0.07%
+1.75K
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
1.65K
0.07%
--
--
Dec 31, 2024
Two Sigma Investments, LP
1.54K
0.06%
+1.54K
--
Dec 31, 2024
Litchman (Manuel)
1.52K
0.06%
--
--
Feb 19, 2025
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Dimensional US Core Equity 1 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Dimensional US Core Equity 1 ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 14, 2025
Merger
50<1
Jan 14, 2025
Merger
50<1
Jan 14, 2025
Merger
50<1
Jan 14, 2025
Merger
50<1
Apr 03, 2023
Merger
15<1
Apr 03, 2023
Merger
15<1
Date
Type
Ratio
Jan 14, 2025
Merger
50<1
Jan 14, 2025
Merger
50<1
Jan 14, 2025
Merger
50<1
Jan 14, 2025
Merger
50<1
Apr 03, 2023
Merger
15<1
Apr 03, 2023
Merger
15<1
Apr 03, 2023
Merger
15<1
Apr 03, 2023
Merger
15<1